Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2370640
Max Phase: Preclinical
Molecular Formula: C54H79N13O11S2
Molecular Weight: 1150.44
Molecule Type: Unknown
Associated Items:
ID: ALA2370640
Max Phase: Preclinical
Molecular Formula: C54H79N13O11S2
Molecular Weight: 1150.44
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCOc1ccc(C[C@H]2NC(=O)CC3(CCCCC3)SCSC[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](Cc3ccccc3)NC2=O)cc1
Standard InChI: InChI=1S/C54H79N13O11S2/c1-4-78-35-19-17-34(18-20-35)26-37-47(72)63-38(25-33-13-7-5-8-14-33)49(74)66-45(32(2)3)51(76)64-39(27-42(55)68)48(73)65-40(30-79-31-80-54(28-44(70)61-37)21-9-6-10-22-54)52(77)67-24-12-16-41(67)50(75)62-36(15-11-23-59-53(57)58)46(71)60-29-43(56)69/h5,7-8,13-14,17-20,32,36-41,45H,4,6,9-12,15-16,21-31H2,1-3H3,(H2,55,68)(H2,56,69)(H,60,71)(H,61,70)(H,62,75)(H,63,72)(H,64,76)(H,65,73)(H,66,74)(H4,57,58,59)/t36-,37+,38+,39+,40+,41-,45-/m0/s1
Standard InChI Key: CNLVVICQTNBGGO-ACVZXISVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1150.44 | Molecular Weight (Monoisotopic): 1149.5463 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Callahan JF, Ashton-Shue D, Bryan HG, Bryan WM, Heckman GD, Kinter LB, McDonald JE, Moore ML, Schmidt DB, Silvestri JS.. (1989) Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines., 32 (2): [PMID:2521519] [10.1021/jm00122a017] |
Source(1):